Regorafenib with irinotecan beads for colorectal liver spread
Treatments studied
Part of Cancer clinical trials.
This Phase 3 trial tests whether adding a pill called regorafenib to irinotecan “drug-eluting” beads placed in the liver can shrink colorectal cancer that has spread mainly to the liver after standard chemotherapy stops working. If you qualify, it may offer a new combination approach for controlling liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can sign consent
- You have colorectal cancer that has spread to the liver (with scans or biopsy proof)
- Your cancer has not responded to first and second standard chemotherapy
- Your liver is the main place the cancer is, with most tumor burden in the liver
- You have enough blood, liver, and kidney function for treatment
- You have not had certain prior treatments (including TACE, regorafenib, or fruquintinib)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hear when a new Colorectal Cancer Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.